Resumen
We introduced a drug screening platform for patient-derived cells (PDCs) from lung cancer patients. The drug sensitivity results of short-term-cultured PDCs were significantly associated with clinical outcomes in patients with targeted therapy. The PDC drug screening platform was useful to predict the clinical outcomes of patients treated with targeted therapy and facilitated precision medicine for patients without relevant driver oncogenes. We expect that the PDC drug screening platform, as a feasible tool, can be used to guide target therapy for lung cancer patients and may overcome the limitation of genomic assay-based targeted therapy.